Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Bristol-Myers Squibb (BMS)
Scientific Title
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) Plus Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma